Wall Street analyst estimates for None (ALLR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 0.50 |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $143277 | $1.5M | $1.5M | $120000 | 0 | 0 | 0 | 0 | 0 | $320000 |
| Cost of Revenue | 0 | $2.2M | $5.1M | 0 | 0 | $106000 | $120000 | 0 | 0 | 0 |
| Gross Profit | $143277 | -$761495 | -$3.6M | $120000 | 0 | -$106000 | -$120000 | 0 | 0 | $320000 |
| Research & Development | 0 | 0 | 0 | $6.4M | $4.2M | $14.2M | $6.9M | $7.1M | $6.1M | $6.6M |
| Selling, General & Admin | $272392 | $3.1M | $1.3M | $3.9M | $4.1M | $12.4M | $10.0M | $10.0M | $11.4M | $6.3M |
| Operating Expenses | $4.6M | $3.1M | $1.4M | $17.7M | $8.3M | $26.6M | $34.5M | $17.1M | $27.2M | $12.9M |
| Operating Income | -$4.5M | -$3.8M | -$5.0M | -$17.6M | -$8.3M | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M |
| EBITDA | -$4.2M | -$3.8M | -$4.9M | -$15.6M | -$6.0M | -$25.8M | -$17.3M | -$11.3M | -$24.2M | -$11.0M |
| Interest Expense | $43697 | $2417 | $233236 | $3.3M | $320000 | $640000 | $223000 | $498000 | $653000 | $185000 |
| Pre-tax Income | -$4.4M | -$5.0M | -$3.5M | -$19.0M | -$6.4M | -$26.5M | -$17.6M | -$11.8M | -$24.9M | -$11.2M |
| Income Tax | -$766892 | -$95086 | -$1.1M | -$4.6M | $198000 | $133000 | -$1.5M | $83000 | -$381000 | 0 |
| Net Income | -$3.7M | -$4.9M | -$2.3M | -$14.3M | -$6.6M | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
| EPS | $0.00 | $0.00 | $0.00 | $-189613.00 | $-1698639.00 | $-79074.18 | $-31799.09 | $-6031.31 | $-15.79 | $-0.78 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $-189613.00 | $-1698639.00 | $-79074.18 | $-31799.09 | $-6031.31 | $-15.79 | $-0.78 |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | $75485 | $4 | $7570 | $11341 | $3.3M | $1.6M | $14.4M |
Related companies: BCTX · CASI · CING · CLSD · CRIS · ENTO · KAPA
More sections of ALLR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks